10x Genomics Stock News

The growth selloff continues to persist and with the Ukraine war raging, persistent inflation and rate hikes on the horizon, it makes sense that high multiple growth is largely out of favor.

During the last session, 10x Genomics Inc. (NASDAQ:TXG)’s traded shares were 0.71 million. At the end of the trading day, the stock’s price was $61.67, reflecting an intraday loss of -8.16% or -$5.48. The 52-week high for the TXG share is $208.99, that puts it down -238.88 from that peak though still a striking -5.64% … 10x Genomics Inc. (NASDAQ: TXG) Stock Dropped -35.83% Over A Month – Is There Any Hope Of A Gain? Read More »

PLEASANTON, Calif., March 1, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference. 10x Genomics''…

10X Genomics (TXG) was added as a new short idea at Hedgeye, which sees a deceleration in NIH funding in terms of new funded scientists, a key input for Hedgeye''s revenue…

10x Genomics <> reached a new 52-week low on Thursday as analysts trimmed their price targets on the stock in reaction to the company’s Q4 2021 earnings release

Investors were disappointed with the company''s 2022 guidance.

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

The stock fell by nearly 25% as markets reacted to the lab tools firm''s 2022 revenue outlook.

Investors were disappointed with the company's 2022 guidance.

10x Genomics Inc (NASDAQ: TXG ) reported Q4 sales of $143.5 million , missing the consensus of $148.53 million. Sales increased 28% Y/Y, primarily due to increased consumables revenue driven by growth in cumulative instruments sold. The gross margin was 81% for the fourth quarter of 2021 compared to 83% a year ago. The decrease … Full story available on Benzinga.com

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2021 Results - Earnings Call Transcript

10x Genomics <> is trading ~18% lower in the post-market on Wednesday after the company set its 2022 revenue guidance below Wall Street forecasts despite a strong revenue beat for…

PLEASANTON, Calif., Feb. 16, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided outlook for 2022. Recent Highlights Revenue was $490.5 million for the full year and $143.5 million…

10x Genomics (NASDAQ:TXG) is scheduled to announce Q4 earnings results on Wednesday, February 16th, after market close.The consensus EPS Estimate is -$0.03 (+99.2% Y/Y) and the…